Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis
- PMID: 9733266
- DOI: 10.1038/sj.bmt.1701334
Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis
Abstract
Randomized, prospective studies comparing BUCY to TBI conditioning regimens for allogeneic bone marrow transplantation have yielded conflicting results. We investigated the overall survival, the disease-free survival and the toxicities of BUCY vs TBI-based regimens by conducting a meta-analysis of all published, randomized, prospective trials comparing these regimens. Five studies were analyzed. We evaluated six endpoints: survival, disease-free survival, veno-occlusive disease (VOD) of the liver, acute GVHD, chronic GVHD, and interstitial pneumonitis. We combined individual study results using a random effects model. Survival and disease-free survival were better with TBI-based regimens than with BUCY, but these differences were not statistically significant (survival odds ratio 1.4, 95% confidence interval 0.9-2.2, P = 0.09; disease-free survival odds ratio 1.2, 95% confidence interval 0.7-2.1, P = 0.44). A power analysis indicated that BUCY was unlikely to have a clinically relevant survival or disease-free survival advantage. The power analysis could not exclude the possibility of such an advantage for TBI-based regimens. A significantly greater incidence of VOD occurred with BUCY (odds ratio 2.5, 95% confidence interval 1.2-5.2, P = 0.02). For the other side-effects, there were no significant differences. We concluded that TBI-based regimens cause less VOD than BUCY and are at least as good for survival and disease-free survival.
Similar articles
-
Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.Haematologica. 2002 Jan;87(1):52-8. Haematologica. 2002. PMID: 11801465
-
The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.Bone Marrow Transplant. 2000 May;25(9):915-24. doi: 10.1038/sj.bmt.1702377. Bone Marrow Transplant. 2000. PMID: 10800057 Clinical Trial.
-
Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study.Bone Marrow Transplant. 2003 Sep;32(6):543-8. doi: 10.1038/sj.bmt.1704198. Bone Marrow Transplant. 2003. PMID: 12953124 Clinical Trial.
-
New preparative regimens with diaziquone or cytarabine in combination with busulfan and cyclophosphamide.Semin Oncol. 1993 Aug;20(4 Suppl 4):56-63; quiz 64. Semin Oncol. 1993. PMID: 8342077 Review.
-
The development of busulfan/cyclophosphamide preparative regimens.Semin Oncol. 1993 Aug;20(4 Suppl 4):12-6; quiz 17. Semin Oncol. 1993. PMID: 8342070 Review.
Cited by
-
Reduced incidence of interstitial pneumonitis after allogeneic hematopoietic stem cell transplantation using a modified technique of total body irradiation.Sci Rep. 2016 Nov 10;6:36730. doi: 10.1038/srep36730. Sci Rep. 2016. PMID: 27830767 Free PMC article.
-
Factors associated with pulmonary toxicity after myeloablative conditioning using fractionated total body irradiation.Radiat Oncol J. 2017 Sep;35(3):257-267. doi: 10.3857/roj.2017.00290. Epub 2017 Sep 29. Radiat Oncol J. 2017. PMID: 29037020 Free PMC article.
-
A Review of Radiation-Induced Coagulopathy and New Findings to Support Potential Prevention Strategies and Treatments.Radiat Res. 2016 Aug;186(2):121-40. doi: 10.1667/RR14406.1. Epub 2016 Jul 26. Radiat Res. 2016. PMID: 27459701 Free PMC article.
-
Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell Transplantation.Transplant Cell Ther. 2024 Oct;30(10):1013.e1-1013.e12. doi: 10.1016/j.jtct.2024.08.005. Epub 2024 Aug 8. Transplant Cell Ther. 2024. PMID: 39122188
-
Safety of total body irradiation using intensity-modulated radiation therapy by helical tomotherapy in allogeneic hematopoietic stem cell transplantation: a prospective pilot study.J Radiat Res. 2020 Nov 16;61(6):969-976. doi: 10.1093/jrr/rraa078. J Radiat Res. 2020. PMID: 32888029 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical